Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.

Journal: Journal Of Medicinal Chemistry
Published:
Abstract

SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), also known as Brahma homologue (BRM), is a Snf2-family DNA-dependent ATPase. BRM and its close homologue Brahma-related gene 1 (BRG1), also known as SMARCA4, are mutually exclusive ATPases of the large ATP-dependent SWI/SNF chromatin-remodeling complexes involved in transcriptional regulation of gene expression. No small molecules have been reported that modulate SWI/SNF chromatin-remodeling activity via inhibition of its ATPase activity, an important goal given the well-established dependence of BRG1-deficient cancers on BRM. Here, we describe allosteric dual BRM and BRG1 inhibitors that downregulate BRM-dependent gene expression and show antiproliferative activity in a BRG1-mutant-lung-tumor xenograft model upon oral administration. These compounds represent useful tools for understanding the functions of BRM in BRG1-loss-of-function settings and should enable probing the role of SWI/SNF functions more broadly in different cancer contexts and those of other diseases.

Authors
Julien P Papillon, Katsumasa Nakajima, Christopher Adair, Jonathan Hempel, Andriana Jouk, Rajeshri Karki, Simon Mathieu, Henrik Möbitz, Rukundo Ntaganda, Troy Smith, Michael Visser, Susan Hill, Felipe Hurtado, Gregg Chenail, Hyo-eun Bhang, Anka Bric, Kay Xiang, Geoffrey Bushold, Tamara Gilbert, Anthony Vattay, Julie Dooley, Emily Costa, Isabel Park, Ailing Li, David Farley, Eugen Lounkine, Q Yue, Xiaoling Xie, Xiaoping Zhu, Raviraj Kulathila, Daniel King, Tiancen Hu, Katarina Vulic, John Cantwell, Catherine Luu, Zainab Jagani